Dr Reddy’s and Sanofi partner to launch Beyfortus, a novel drug to prevent respiratory syncytial virus in infants.

Under the arrangement, Dr Reddy's will have exclusive rights from Sanofi to promote and distribute Beyfortus in India.

Dr Reddy’s & Sanofi Healthcare expand partnership to unveil Beyfortus, a novel drug to prevent RSV in India: Our Bureau, Bengaluru Tuesday, April 29, 2025, 12:15 Hrs [IST] Dr Re ...

Under the agreement, Dr Reddy's will have exclusive rights from SHIPL to promote and distribute Beyfortus within the country ...

AstraZeneca reports mixed first-quarter 2025 results. The fall in pre-market is likely due to the soft sales performance of ...

Beyfortus, which has been approved for use in the European Union, US, China, Japan, among several countries globally, received its marketing authorisation approval from India’s Central Drugs ...

Dr Reddy's Laboratories has partnered with Sanofi Healthcare to introduce Beyfortus, a novel drug for RSV prevention in ...

Swedish Orphan Biovitrum AB (BIOVF) reports robust revenue growth driven by haematology, while facing challenges in immunology and strategic market expansions.

Sanofi Q1 2025 revenue rose 10.8% to $10.42 billion, driven by Dupixent and new launches, as earnings climbed 20.1% and 2025 guidance was reaffirmed.

Investing.com -- Swedish Orphan Biovitrum shares climbed 3% as the company reported a first-quarter revenue of SEK 6.45 billion marking a 3% increase YoY and surpassing consensus expectations by the ...

Dr. Reddy's Laboratories has expanded its partnership with Sanofi Healthcare to introduce Beyfortus, a novel drug preventing ...

Dr. Reddy’s Laboratories will expand its partnership with Sanofi Healthcare India (SHIPL) by launching the latter’s novel drug Beyfortus (nirsevimab) in India.